- Home
- PPBT vs KTTA Comparison
PPBT vs KTTA Comparison
Compare PPBT & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- KTTA
- Stock Information
- Founded
- PPBT 2010
- KTTA 2020
- Country
- PPBT Israel
- KTTA United States
- Employees
- PPBT N/A
- KTTA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- KTTA Health Care
- Exchange
- PPBT Nasdaq
- KTTA Nasdaq
- Market Cap
- PPBT 5.5M
- KTTA 5.7M
- IPO Year
- PPBT N/A
- KTTA 2021
- Fundamental
- Price
- PPBT $0.59
- KTTA $0.72
- Analyst Decision
- PPBT Strong Buy
- KTTA
- Analyst Count
- PPBT 1
- KTTA 0
- Target Price
- PPBT $33.00
- KTTA N/A
- AVG Volume (30 Days)
- PPBT 234.5K
- KTTA 86.1K
- Earning Date
- PPBT 11-14-2025
- KTTA 11-12-2025
- Dividend Yield
- PPBT N/A
- KTTA N/A
- EPS Growth
- PPBT N/A
- KTTA N/A
- EPS
- PPBT N/A
- KTTA N/A
- Revenue
- PPBT N/A
- KTTA N/A
- Revenue This Year
- PPBT N/A
- KTTA N/A
- Revenue Next Year
- PPBT N/A
- KTTA N/A
- P/E Ratio
- PPBT N/A
- KTTA N/A
- Revenue Growth
- PPBT N/A
- KTTA N/A
- 52 Week Low
- PPBT $0.53
- KTTA $0.65
- 52 Week High
- PPBT $13.95
- KTTA $4.35
- Technical
- Relative Strength Index (RSI)
- PPBT 29.54
- KTTA 44.71
- Support Level
- PPBT $0.56
- KTTA $0.69
- Resistance Level
- PPBT $0.66
- KTTA $0.78
- Average True Range (ATR)
- PPBT 0.04
- KTTA 0.04
- MACD
- PPBT 0.05
- KTTA -0.00
- Stochastic Oscillator
- PPBT 29.11
- KTTA 18.87
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).